CFO
EW icon

CVA Family Office’s Edwards Lifesciences EW Stock Holding History

CVA Family Office’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Sell
1,295
-8
-0.6% -$670 0.01% 445
2026
Q1 		$104K Buy
1,303
+287
+28% +$23.7K 0.01% 448
2025
Q4 		$86.6K Sell
1,016
-101
-9% -$8.29K 0.01% 445
2025
Q3 		$86.9K Buy
1,117
+37
+3% +$2.89K 0.01% 445
2025
Q2 		$84.5K Buy
1,080
+276
+34% +$20.6K 0.01% 435
2025
Q1 		$58.3K Sell
804
-169
-17% -$12.1K 0.01% 493
2024
Q4 		$72K Buy
973
+799
+459% +$55.9K 0.01% 447
2024
Q3 		$11.5K Sell
174
-1,628
-90% -$118K ﹤0.01% 737
2024
Q2 		$166K Sell
1,802
-85
-5% -$7.53K 0.03% 267
2024
Q1 		$180K Hold
1,887
– – 0.03% 262
2023
Q4 		$144K Buy
+1,887
New +$131K 0.03% 283
2023
Q3 		– Sell
-2,199
Closed -$207K – 470
2023
Q2 		$207K Buy
2,199
+8
+0.4% +$695 0.04% 218
2023
Q1 		$181K Buy
+2,191
New +$172K 0.04% 231
2022
Q4 		– Sell
-1,624
Closed -$134K – 967
2022
Q3 		$134K Sell
1,624
-1,190
-42% -$115K 0.04% 210
2022
Q2 		$268K Buy
2,814
+695
+33% +$71.9K 0.07% 140
2022
Q1 		$249K Buy
2,119
+340
+19% +$38.1K 0.06% 157
2021
Q4 		$230K Buy
1,779
+1,074
+152% +$125K 0.06% 159
2021
Q3 		$56K Sell
705
-1,364
-66% -$156K 0.04% 171
2021
Q2 		$214K Buy
2,069
+939
+83% +$88.5K 0.06% 152
2021
Q1 		$95K Buy
1,130
+425
+60% +$35.9K 0.04% 184
2020
Q4 		$64K Hold
705
– – 0.04% 165
2020
Q3 		$56K Buy
705
+405
+135% +$31.6K 0.04% 171
2020
Q2 		$21K Buy
+300
New +$21.3K 0.02% 216

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CVA Family Office's EW Position: Q2 2026 in Review

CVA Family Office reduced its Edwards Lifesciences (EW) stake by 0.61% in Q2 2026, selling an estimated $670 and leaving 1,295 shares worth $117K. The position accounts for 0.01% of the portfolio, ranked #445.

CVA Family Office first reported a position in EW in Q2 2020 and has held it in 23 quarters since. The position peaked at $268K in Q2 2022. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • CVA Family Office held 1,295 shares of Edwards Lifesciences worth $117K as of Q2 2026.
  • CVA Family Office sold 8 Edwards Lifesciences shares in Q2 2026, an estimated $670.
  • Edwards Lifesciences made up 0.01% of CVA Family Office's portfolio in Q2 2026, its #445 holding.
  • CVA Family Office first reported a position in Edwards Lifesciences in Q2 2020 and has held it in 23 quarters since.
  • CVA Family Office's Edwards Lifesciences position peaked at $268K in Q2 2022.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.